AC Immune

The global central nervous system therapeutics market, valued at USD 144.3M in 2024, is projected to reach USD 431M by 2035, growing at a CAGR of 10.46%. Growth drivers include rising neurological disorders, advancements in drug development, and increased R&D investments. Key segments include mental health and neurodegenerative diseases, with CNS stimulants and anticonvulsants leading in drug class. North America leads in revenue, while Asia Pacific is the fastest-growing region.

GlobalData assesses drug development using phase transition and approval likelihood scores. Semorinemab, targeting tau protein for Alzheimer’s, is a humanized IgG4 antibody. AC Immune focuses on neurodegenerative diseases, leveraging SupraAntigen and Morphomer technologies.

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.

The neurodegenerative disorder therapeutics market is projected to grow from $18.53 billion in 2023 to $28.33 billion in 2028 at a CAGR of 9.0%, driven by factors like aging population, rising prevalence of neurodegenerative disorders, and strategic collaborations among pharmaceutical companies.

AC Immune reported Q3 2024 progress, including advancing its Parkinson’s Phase 2 trial and receiving a CHF 24.6 million milestone payment for Alzheimer’s Phase 2b trial. The company achieved a positive net income of CHF 5.5 million, with a strong cash position of CHF 157.9 million, and aims for continued growth in neurodegenerative disease market.

Long-term cardiovascular drug use linked to fewer dementia diagnoses; anti-platelet use increases risk. Fampridine improves working memory in low-performing adults. MS not a barrier to immune checkpoint inhibitors for cancer. AI identifies Chiari type-1 malformation phenotypes. AI-enabled devices may impact neurology prognoses. ACI-7104.056 induces high anti-alpha-synuclein antibodies in early Parkinson's. Rest tremor correlated with preserved dopamine levels. Hospital care standards proposed for Parkinson's patients. Nerivio migraine treatment device expanded to pediatric use. AI-driven MRI software detects ARIA in Alzheimer's patients. ARIA with edema has no long-term cognitive effect in early Alzheimer's. Systemic dexamethasone improves survival free of cerebral palsy in high-risk bronchopulmonary dysplasia cases. Cancer survivors less likely to develop Alzheimer's. AARP partners to identify dementia risk factors.

ACI-7104, a Parkinson’s vaccine, shows safety and high anti-alpha-synuclein antibody levels in Phase 2 trial, with further updates expected in 2025. The vaccine aims to trigger an immune response against toxic alpha-synuclein, potentially slowing disease progression.

AC Immune's stock surged 26.9% after Phase II VacSYn trial data showed all patients responded to its Parkinson's disease vaccine-like immunotherapy, ACI-7104.056, targeting alpha-synuclein.